News headlines about Zafgen (NASDAQ:ZFGN) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zafgen earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 47.5335676094829 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern’s analysis:
- Zacks: Brokerages Anticipate Zafgen Inc (ZFGN) Will Post Earnings of -$0.52 Per Share (americanbankingnews.com)
- Stock Spotlight: Zafgen, Inc. (ZFGN), On Track Innovations Ltd. (OTIV) (newsregistrar.com)
- Tips For Effortless money: Rambus Inc. (NASDAQ:RMBS), Briggs & Stratton Corporation (NYSE:BGG), Zafgen, Inc … (thestreetpoint.com)
- Zafgen to Present at the Wedbush PacGrow Healthcare Conference (finance.yahoo.com)
- Zafgen, Inc. (ZFGN) CEO Jeffrey Hatfield on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
Several research firms recently weighed in on ZFGN. Wedbush began coverage on shares of Zafgen in a research note on Thursday, August 2nd. They issued an “outperform” rating and a $14.00 target price for the company. Zacks Investment Research raised shares of Zafgen from a “sell” rating to a “hold” rating in a research note on Monday, July 16th. BidaskClub raised shares of Zafgen from a “hold” rating to a “buy” rating in a research note on Tuesday, July 3rd. Piper Jaffray Companies began coverage on shares of Zafgen in a research note on Tuesday, July 3rd. They issued an “overweight” rating and a $18.00 target price for the company. Finally, ValuEngine raised shares of Zafgen from a “hold” rating to a “buy” rating in a research note on Tuesday, June 26th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Zafgen currently has an average rating of “Buy” and a consensus target price of $15.25.
Zafgen (NASDAQ:ZFGN) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.02. equities analysts predict that Zafgen will post -2.05 earnings per share for the current fiscal year.
In other Zafgen news, insider Thomas E. Hughes sold 32,000 shares of the firm’s stock in a transaction on Thursday, June 28th. The stock was sold at an average price of $10.00, for a total transaction of $320,000.00. Following the completion of the sale, the insider now owns 125,247 shares of the company’s stock, valued at approximately $1,252,470. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 23.70% of the company’s stock.
Zafgen Company Profile
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Read More: How Short Selling Works
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.